Holen Sie sich die Stockscreener-App
15.98
18.79%
2.4603
Schlusskurs vom Vortag:
$13.52
Offen:
$13.64
24-Stunden-Volumen:
3.21M
Relative Volume:
2.39
Marktkapitalisierung:
$806.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.3307
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+13.90%
1M Leistung:
+48.70%
6M Leistung:
+20.30%
1J Leistung:
+65.06%
1-Tages-Spanne:
$13.37
$16.49
1-Wochen-Bereich:
$13.28
$16.49
52-Wochen-Spanne:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.96 | 683.39M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.10 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
732.36 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.77 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
928.95 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.90 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment - MSN
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Behavioral Patterns of KALV and Institutional Flows - news.stocktradersdaily.com
KalVista Pharma CMO Audhya sells $71k in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Stock (KALV) Opinions on Q3 Revenue Success - Quiver Quantitative
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
KalVista Pharma CFO Piekos sells $60k in shares By Investing.com - Investing.com Canada
KalVista Pharma exec Yea sells $58k in shares By Investing.com - Investing.com Nigeria
KalVista Pharma CMO Audhya sells $71k in stock - Investing.com
KalVista Pharma exec Yea sells $58k in shares - Investing.com
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Officer Audhya Acquires 5,954 Of KalVista Pharmaceuticals Inc [KALV] - TradingView
KalVista Pharmaceuticals, Inc. (KALV) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycle2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Insider Monkey
10 Best Breakout Stocks to Invest In - Insider Monkey
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates - MSN
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockJuly 2025 Review & Reliable Momentum Entry Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kalvista Pharmaceuticals Inc-Aktie (KALV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 24 '25 |
Sale |
13.45 |
4,331 |
58,256 |
223,508 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 24 '25 |
Sale |
13.45 |
5,296 |
71,236 |
131,831 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 24 '25 |
Sale |
13.45 |
10,940 |
147,154 |
416,189 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 20 '25 |
Option Exercise |
0.00 |
87,390 |
376 |
220,964 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 18 '25 |
Sale |
14.48 |
4,466 |
64,665 |
403,879 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Nov 18 '25 |
Sale |
14.48 |
2,683 |
38,848 |
133,574 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Nov 18 '25 |
Sale |
14.48 |
3,075 |
44,524 |
125,877 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Nov 12 '25 |
Sale |
11.55 |
3,328 |
38,438 |
398,981 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Sep 08 '25 |
Sale |
15.84 |
7,294 |
115,537 |
395,189 |
| Sweeny Nicole | Chief Commercial Officer |
Aug 25 '25 |
Sale |
13.42 |
1,480 |
19,862 |
32,291 |
0.66%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):